Dr Simon Craw – VP of Business Development – International Stem Cell Corp. (OTCQB:ISCO)


.
.
.
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCellTM. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care.

 

0 Comments

You can be the first one to leave a comment.

Leave a Comment

 
 




 

 

Be Heard

theStockRadio.com is dedicated to getting your company’s voice heard. From Bluechip's to Small Cap and OTC companies, our dedicated audience is interested in what you have to say. The markets are ever-changing, so it's important to use as many resources as you can. theStockRadio.com is here to help, so hurry up and let us get the word out for you!
 
x
Name:
Email: